Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 - 5. (Cancelled).

Claim 6. (Currently amended) A compound according to formula V in free or pharmaceutically acceptable salt form



wherein

R_{11} is pyrimidyl;

X is $-NR_6-Y-$, -O- or -S-,

wherein R_6 is H, C_1-C_4alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, C_7-C_{19}aralkyl or C_4-C_{19}heteroaralkyl, and -Y- is C_1-C_4alkylene or a direct bond;

R_{12} is phenyl, optionally substituted by one or more substituents, each of which is independently selected from

halo,

CF_3,

cyano,

amido or thioamido which is optionally mono- or di-N-substituted by C_1-C_4alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substituted,

carboxylate or thiocarboxylate optionally in the form of an optionally halo-substituted C_1-C_{10}alkoxy, C_2-C_{10}alkenoxy, C_2-C_{10}alkynoxy, C_3-C_7cyclalkoxy, C_5-C_7cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester, optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkyl optionally C_1-C_4alkyl- or C_3-C_5cycloalkyl-substituted-carbonyl or -thiocarbonyl,

optionally halo-substituted-C_1-C_4alkoxy, C_2-C_4alkenoxy, C_2-C_4alkynoxy, C^3_3-C^5_5cycloalkoxy or C^3_3-C^5_5cyclothioalkoxy,

optionally halo substituted C_1-C_4 alkyl,

oxycarbonyl or optionally N-C_1-C_4alkyl-substituted aminocarbonyl both of which are optionally C_1-C_4alkyl or C_3-C_5cycloalkyl substituted (including thiocarbonyl analogues thereof),

optionally mono- or di-C_1-C_4alkyl-substituted -C_0-C_1alkylamine which is optionally mono- or di-N-C_1-C_4 alkyl substituted,

optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkyl optionally N-C_1-C_4alkyl-substituted amino-carbonyl or -thiocarbonyl,

optionally N-C_1-C_4 alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by

optionally mono- or -di-N-C_1-C_4alkyl-substituted amino,

a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C_1-C_4 alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substituted, or

sulphinyl or sulphonyl optionally substituted by

optionally halo-substituted-C_1-C_4alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl,

optionally mono- or di-N-C_1-C_4alkyl-substituted amino,

a nitrogen atom which form a heterocyclic rind of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substituted;

R_{13} is H, amino, C_1-C_{10}alkyl, C_3-C_{10}cycloalkyl, C_3-C_{18}heterocycloalkyl, C_6-C_{18}aryl, or C_3-C_{18}heteroaryl all optionally substituted by up to 4 substituents separately selected from C_1-C_4alkyl, halogen, halo-substututed-C_1-C_4alkyl, hydroxyl, C_1-C_4alkoxy, C_1-C_4alkylthio, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, C_6-C_{18}arylC_1-C_4alkyl, C_3-C_{18}heteroarylC_1-C_4alkyl, C_3-C_{18}heterocycloalkyl or optionally mono- or di-N-C_1-C_4alkyl substituted amino all of which are optionally substituted by halo, hydroxyl, C_1-C_4alkyl, C_1-C_4alkoxy or C_1-C_4alkoxycarbonyl; and

R_{14} is C_1-C_{10}alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, or C_3-C_{12}cycloalkyl optionally substituted by up to 3 substituents separately selected from C_1-C_4alkyl, halogen, halo-substitued-C_1-C_4alkyl, hydroxyl, C_1-C_4alkoxy, C_1-C_4alkylthio, optionally mono- or di-N-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N[[,]]

~~and pharmaceutically-acceptable and -cleavable esters thereof and acid addition sales thereof~~.

Claim 7. (Currently amended) A compound according to claim 6 of formula V' in free or pharmaceutically acceptable salt form



V'

wherein

R_{14}' is phenyl or C_3-C_7cycloalkyl each of which is optionally mono-substituted by halogen, C_1-C_4alkyl, C_1-C_4alkoxy, hydroxyl, trihalomethyl optionally mono- or di-N-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N;

R_{10} is halogen, CF_3, C_1-C_4alkyl or C_1-C_4alkoxy;

R_{13}' is pyridyl, pyrimidyl, piperazinyl, piperidinyl, NR_9R_{10}, $-CH_2OH$, $CH_2NR_{15}R_{16}$, $-CH2CH_2R_{15}R_{16}$, or Het-C_1-C_4alkyl-,

wherein

R_9 and R_{10} are separately selected from H, C_1-C_4alkyl, C_6-C_{18}aryl, C_3-C_{18} heteroaryl, C_6-C_{18}arylC_1-C_4alkyl, C_3-C_{18}heteroarylC_1-C_4alkyl all of which are optionally substituted by halo, hydroxyl, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4alkoxycarbonyl[[,]] ;

~~R_{11} and R_{12} are separately selected from H or C_1-C_6alkyl, and~~

Het ~~is N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom (e.g. O,S or N)~~ is a N-heterocyclyl containing from 5 to 7 ring atoms where said ring atoms optionally containing a further heteroatom selected from the group consisting of O, S, and N;

R_{15} and R_{16} are independently selected from H and C_1-C_4 alkyl;

X" is -NH-Y'-, -O- or -S-, where Y' is 'CH_2-, $-CH_2-CH_2$-, $-CH_9(CH_3)$- or a direct bond~~, and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof~~.

Claim 8. (Currently amended) A compound according to claim 6 selected from:

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidino-N-2-ethyl)imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(N,N-diethylamino-N-2-ethyl)imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino-N-2-ethyl)imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(isopropylamino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyrrolidino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-pyridyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-pyridyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(aminoimidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(aminoimidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(S)-phenylethyl)amino- 4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-((4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-((4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-((4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-piperidinyl) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-methyl-4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-(2-hydroxy-2-methyl)propyl-4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(benzylamino) imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-fluorophenyl amino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyridyl-4-amino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-ethoxycarbonyl piperidine-4-amino)imidazo[4,5-b]pyridine; and
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidine-4-amino)imidazo[4,5-b]pyridine[[;]].

Claim 9. (Currently amended) A process for the production of

(i) ~~an Agent of the Invention~~ a compound of formula V" in free or pharmaceutically acceptable salt form



V"

wherein

R_{11} is pyrimidyl;[[,]]

R_{12}[[,]] is phenyl, optionally substituted by one or more substituents, each of which is independently selected from

halo,

CF_3,

cyano,

amido or thioamido which is optionally mono- or di-N-substituted by C_1-C_4alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substituted,

carboxylate or thiocarboxylate optionally in the form of an optionally halo-substituted C_1-C_{10}alkoxy, C_2-C_{10}alkenoxy, C_2-C_{10}alkynoxy, C_3-C_7cyclalkoxy, C_5-C_7cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester, optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkyl optionally C_1-C_4alkyl- or C_3-C_5cycloalkyl-substituted-carbonyl or -thiocarbonyl,

optionally halo-substituted-C_1-C_4alkoxy, C_2-Calkenoxy, C_2-Calkynoxy, C_3-C_5cycloalkoxy or C_3-C_5cyclothioalkoxy,

optionally halo substituted C_1-C_4 alkyl,
oxycarbonyl or optionally N-C_1-C_4alkyl-substituted aminocarbonyl both of which are optionally C_1-C_4alkyl or C_3-C_5cycloalkyl substituted (including thiocarbonyl analogues thereof),
optionally mono- or di-C_1-C_4alkyl-substituted -C_0-C_1alkylamine which is optionally mono- or di-N-C_1-C_4 alkyl substituted,
optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkyl optionally N-C_1-C_4alkyl-substituted amino-carbonyl or -thiocarbonyl,
optionally N-C_1-C_4 alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by
optionally mono- or -di-N-C_1-C_4alkyl-substituted amino,
a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C_1-C_4 alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substituted, or
sulphinyl or sulphonyl optionally substituted by
optionally halo-substituted-C_1-C_4alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl,
optionally mono- or di-N-C_1-C_4alkyl-substituted amino,
a nitrogen atom which form a heterocyclic rind of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substituted;

R_{14} is C_1-C_{10}alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, or C_3-C_{12}cycloalkyl optionally substituted by up to 3 substituents separately selected from C_1-C_4alkyl, halogen, halo-substitued-C_1-C_4alkyl, hydroxyl, C_1-C_4alkoxy, C_1-C_4alkylthio, optionally mono- or di-N-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N ~~and~~ ;

X is -NR_6-Y-, -O- or -S-, wherein R_6 is H, C_1-C_4alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, C_7-C_{19}aralkyl or C_4-C_{19}heteroaralkyl, and -Y- is C_1-C_4alkylene or a direct bond;
~~are as previously defined and~~

R_{13}" is -CH_2-$CH_2NR_{15}R_{16}$ or - CH_2-CH_2-Het wherein

R_{15}[[,]] and R_{16} are independently selected from H and C_1-C_4 alkyl; and

Het ~~are as previously defined~~ is a N-heterocyclyl containing from 5 to 7 ring atoms where said ring atoms optionally containing a further heteroatom selected from the group consisting of O, S, and N;

comprising reacting a corresponding vinyl precursor of formula VI



VI

wherein R_{11}, R_{12}, R_{14} and X are as previously defined with the corresponding amine of formula $HNR_{15}R_{16}$ or N-heterocycloalkyl ring compound;

(ii) ~~an Agent of the Invention~~ a compound of formula V according to claim 6



V

wherein R_{13} is aryl or heteroaryl comprising arylation or heteroarylation of a compound of formula VII



VII

wherein R_{11}, R_{12}, R_{14} and X are as previously defined in claim 6;

(iii) ~~an Agent of the Invention~~ a compound of formula V according to claim 6

wherein R_{13} is -N-heterocycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, -NH-(C_1-C_4alkyl)-heterocycloalkyl, -NH-(C_1-C_4alkyl)-aryl, -NH-(C_1-C_4alkyl)-heteroaryl, or -NH-(C_1-C_4alkyl)-heterocycloalkyl comprising coupling a corresponding chloroprecursor compound of formula VII, as defined above, with the corresponding N-heterocycloalkyl compound or amine;

(iv) ~~an Agent of the Invention~~ a compound of formula V according to claim 6

in which R_{13} is -NH_2, comprising reacting the corresponding methyl sulphinyl compound of formula VIII'



VIII'

wherein R_{11} and R_{12} are as previously defined in claim 6;

(v) ~~an Agent of the Invention~~ a compound of formula V according to claim 6

in which R_{13} is piperazinyl, comprising reacting a corresponding methylsulphinyl compound of formula VIII"



VIII"

wherein R_{11} and R_{12} are as previously defined in claim 6 and P is an N protecting group, with the corresponding amine of formula R_{14}-NH_2; and

(vi) recovering the resultant compounds of formula (V") or (V) in free or pharmaceutically acceptable salt form.

Claims 10 - 13. (Cancelled).